Latest Administration News

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Auric Mining Limited reports a robust cash flow quarter ending December 31, 2024, with current assets reaching approximately $10 million and ongoing cash inflows from its joint venture at Jeffreys Find Gold Mine.

Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.

Leo Lithium has completed the sale of its remaining interest in the Goulamina Project, distributing over A$249 million to shareholders and restructuring its board as it pivots towards new asset acquisitions.

Leo Lithium Limited reports a robust cash position of $269.3 million following the sale of a 40% stake in MLBV, underpinning its financial strength amid ongoing operational expenditures.

Hastings Technology Metals Ltd reported a $2.29 million net cash outflow from operating activities in the December 2024 quarter, alongside significant capital expenditure and new borrowings, highlighting a critical phase in its project development.

Equity Story Group Ltd (ASX:EQS) reports a robust December quarter marked by significant growth in funds under management, membership fees, and capital markets revenue, alongside strategic cost reductions positioning the company for sustained 2025 growth.

Magnum Mining and Exploration Limited reported a net cash outflow of $87.68k for Q4 2024, ending the quarter with $332.81k in cash and a substantial $11 million in unused financing facilities.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

Galena Mining Limited reports a challenging December quarter at its 60%-owned Abra Base Metals Mine, marked by production declines and ongoing voluntary administration. The company appoints a new CEO for Abra and explores recapitalisation options to stabilise operations.